Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2016 Sep 16;15(12):3028–3039. doi: 10.1158/1535-7163.MCT-16-0366

Fig. 6. HER2-positive cancer cells are resistant to FAK-kinase inhibition.

Fig. 6

Matrigel on-top 3D growth assays with (A) a panel of breast cancer cell lines and (B) MCF7-HER2 isogenic line (Tet-Off) treated with titrating doses of defactinib. HER2 positivity confers resistance to defactinib treatment (IC50 values shown below graph). Viability values shown are averaged results from triplicate measurements in three independent experiments. Error bars shown represent 95% confidence intervals. The immunoblot right of (B) shows HER2 knockdown with 1µg/mL doxycycline treatment.